BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35769257)

  • 1. Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.
    Dai D; Li Q; Zhou P; Huang J; Zhuang H; Wu H; Chen B
    Front Cell Dev Biol; 2022; 10():874588. PubMed ID: 35769257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
    Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
    Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
    Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
    J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma.
    Zhang L; Zhu P; Tong Y; Wang Y; Ma H; Xia X; Zhou Y; Zhang X; Gao F; Shu P
    Onco Targets Ther; 2019; 12():7005-7014. PubMed ID: 31695415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy.
    Lin J; Xu X; Sun D; Li T
    Front Oncol; 2020; 10():626555. PubMed ID: 33680950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    An Y; Bi F; You Y; Liu X; Yang Q
    J Cancer; 2018; 9(21):4058-4071. PubMed ID: 30410611
    [No Abstract]   [Full Text] [Related]  

  • 12. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity.
    Liu S; Liu Y; Ma J; Lv R; Wang F
    Medicine (Baltimore); 2023 Sep; 102(35):e34851. PubMed ID: 37657028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
    Wu M; Sun Y; Wu J; Liu G
    Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer.
    Zhu T; Chen R; Wang J; Yue H; Lu X; Li J
    Cancer Cell Int; 2020; 20():257. PubMed ID: 32565741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
    Zhang H; Wu Y; Li H; Sun L; Meng X
    Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes.
    Meng C; Sun Y; Liu G
    Front Oncol; 2023; 13():1144430. PubMed ID: 37256178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.